Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Colorcon
AstraZeneca
Merck
Mallinckrodt

Last Updated: May 28, 2022

Baricitinib - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

What are the generic sources for baricitinib and what is the scope of patent protection?

Baricitinib is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Baricitinib has fifty-six patent family members in forty-four countries.

One supplier is listed for this compound.

Summary for baricitinib
International Patents:56
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 103
Clinical Trials: 101
Patent Applications: 2,603
What excipients (inactive ingredients) are in baricitinib?baricitinib excipients list
DailyMed Link:baricitinib at DailyMed
Recent Clinical Trials for baricitinib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Fundación de Investigación Biomédica - Hospital Universitario de La PrincesaPhase 4
McGill University Health Centre/Research Institute of the McGill University Health CentreN/A
Marie Hudson, MDN/A

See all baricitinib clinical trials

Pharmacology for baricitinib

US Patents and Regulatory Information for baricitinib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-001 May 31, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-002 Oct 8, 2019 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-001 May 31, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-002 Oct 8, 2019 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-002 Oct 8, 2019 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-001 May 31, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for baricitinib

Country Patent Number Title Estimated Expiration
Colombia 6290658 DERIVADOS DE AZETIDINA Y CICLOBUTANO COMO INHIBIDORES DE JACK See Plans and Pricing
Dominican Republic P2010000270 DERIVADOS DE AZETIDINA Y CICLOBUTANO COMO INHIBIDORES DE JAK See Plans and Pricing
New Zealand 587928 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS See Plans and Pricing
South Korea 20100121657 AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS See Plans and Pricing
Canada 2718271 DERIVES D'AZETIDINE ET DE CYCLOBUTANE EN TANT QU'INHIBITEURS DE JANUS KINASE (JAK) (AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS) See Plans and Pricing
Norway 2017033 See Plans and Pricing
Uruguay 31705 DERIVADOS DE AZETIDINA Y CICLOBUTANO COMO INHIBIDORES DE JAK See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for baricitinib

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2288610 2017/032 Ireland See Plans and Pricing PRODUCT NAME: BARACITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTRATION NO/DATE: EU/1/16/1170 20170213
2288610 132017000078559 Italy See Plans and Pricing PRODUCT NAME: BARICITINIB E I SUOI SALI FARMACEUTICAMENTE ACCETTABILI(OLUMIANT); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1170, 20170215
2288610 1790035-8 Sweden See Plans and Pricing PRODUCT NAME: BARICITINIB; REG. NO/DATE: EU/1/16/1170 20170215
2288610 315 50012-2017 Slovakia See Plans and Pricing PRODUCT NAME: BARICITINIB VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/16/1170 20170215
2288610 2017C/025 Belgium See Plans and Pricing PRODUCT NAME: OLUMIANT - BARICITINIB; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215
2288610 33/2017 Austria See Plans and Pricing PRODUCT NAME: BARICITINIB UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/16/1170 (MITTEILUNG) 20170215
2288610 LUC00027 Luxembourg See Plans and Pricing PRODUCT NAME: BARICITINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Johnson and Johnson
Colorcon
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.